Ovidrel and Autoimmune Disease: What Women with Immune Conditions Need to Know Before Using This Fertility Trigger

What Is Ovidrel and Why Does It Matter for Women with Autoimmune Conditions?

Ovidrel is a prescription-only recombinant human chorionic gonadotropin (r-hCG) given as a single 250 mcg subcutaneous injection to trigger ovulation during fertility treatment. For most women, it is a routine and well-tolerated step in an IVF or intrauterine insemination (IUI) cycle. For women living with autoimmune conditions, lupus (SLE), rheumatoid arthritis (RA), antiphospholipid syndrome (APS), thyroid autoimmunity, or multiple sclerosis, the picture is more layered.

HCG itself is not simply a passive hormone signal. It has direct effects on immune cells, including T-regulatory cells and natural killer (NK) cells, in ways that matter when your immune system is already dysregulated. Your reproductive endocrinologist and rheumatologist or immunologist need to be on the same page before your trigger shot is administered.

The sections below cover the pharmacology women with autoimmune disease need to understand, the specific conditions that require extra planning, ovarian hyperstimulation syndrome (OHSS) risk, and what pregnancy safety data actually shows.

How Ovidrel Works: The Pharmacology Women Need to Understand

The Mechanism of the hCG Trigger

Ovidrel delivers a surge of recombinant hCG that mimics the body's natural mid-cycle LH surge. It binds to LH/hCG receptors on ovarian granulosa and luteal cells, completing the final 36-hour maturation process of the dominant follicle or cohort of follicles before retrieval 1.

Because r-hCG (choriogonadotropin alfa) and urinary-derived hCG share the same receptor, their ovulatory efficacy is equivalent when given at the right time. The advantage of the recombinant form is batch-to-batch consistency and freedom from urinary proteins, which reduces, but does not eliminate, the chance of allergic or immune-mediated reactions.

hCG as an Immune Modulator

This part is rarely explained to patients. HCG is not just an ovarian hormone. During pregnancy, physiological hCG concentrations help shift the maternal immune response toward tolerance of the semi-allogeneic embryo. It does this by:

• Promoting expansion of CD4+CD25+ regulatory T cells (Tregs), the cells that suppress autoimmune attack
• Inhibiting pro-inflammatory natural killer cell activity in the uterine lining
• Reducing secretion of TNF-alpha and IL-6, the cytokines elevated in active RA and SLE

For women with autoimmune disease, this brief, pharmacological hCG exposure may theoretically exert a mild immunosuppressive effect at the time of trigger. Whether that is clinically meaningful from a single 250 mcg dose is not established by controlled trials. The data come from in-vitro studies and from observational pregnancy literature, not from ART-specific randomized studies in autoimmune patients.

The WomanRx Autoimmune-Trigger Framework: Before using Ovidrel, women with systemic autoimmune disease should assess four variables together: (1) current disease activity score, (2) immunosuppressive medication safety in early pregnancy, (3) personal OHSS risk factors, and (4) the presence of antiphospholipid antibodies. None of these considerations is addressed by standard hCG package labeling, but each shapes cycle safety in a meaningful way.

Specific Autoimmune Conditions: What the Evidence Actually Shows

Systemic Lupus Erythematosus (SLE)

Women with SLE have lower ovarian reserve on average than age-matched controls, partly from prior cyclophosphamide exposure and partly from the disease itself. HCG trigger is used routinely in SLE patients undergoing fertility preservation or IVF, but disease activity at the time of stimulation matters enormously.

Active lupus nephritis or a recent flare in the three months before ART is a relative contraindication to proceeding, not because of Ovidrel specifically, but because the hormonal milieu of ovarian stimulation, particularly rising estradiol, can trigger SLE flares in susceptible women. The hCG trigger itself represents a single-point exposure, not prolonged estrogen elevation, so it is the stimulation phase, not the trigger, that carries greater flare risk.

Women with SLE and concurrent antiphospholipid antibodies (a subset of APS, covered below) need thromboprophylaxis planning before any ART cycle, independent of which trigger agent is chosen.

Antiphospholipid Syndrome (APS)

APS is the autoimmune condition most directly relevant to the hCG trigger decision. Antiphospholipid antibodies promote thrombosis and pregnancy loss, and the hyperestrogenic state of controlled ovarian stimulation amplifies that risk by elevating clotting factor activity.

OHSS, which can occur after hCG trigger, adds a further thrombogenic dimension through hemoconcentration and inflammatory cytokine release. Women with triple-positive APS (lupus anticoagulant plus anticardiolipin IgG plus anti-beta2-glycoprotein I IgG) are at the highest thrombotic risk and should have a hematology or rheumatology consultation before any trigger shot is given.

Practical steps before Ovidrel in APS:

• Confirm international normalized ratio (INR) is therapeutic if on warfarin, or that low-molecular-weight heparin is bridged correctly
• Discuss with your team whether a GnRH agonist trigger (where ovarian reserve and protocol allow) can substitute for hCG to reduce OHSS risk, since GnRH agonist triggers are associated with lower OHSS rates in high-risk women
• Ensure thromboprophylaxis continues through the luteal phase and early pregnancy if conception occurs

Rheumatoid Arthritis (RA)

The relationship between RA and fertility is complex. Women with active RA have reduced conception rates compared with the general population, and methotrexate, a mainstay of RA therapy, is a category X teratogen that must be discontinued at least three months before a conception attempt. Leflunomide has an even longer washout requirement (cholestyramine washout protocol, typically 11 days, followed by confirmation that plasma levels are below 0.02 mg/L).

Ovidrel itself does not interact directly with methotrexate or leflunomide pharmacokinetics. The concern is ensuring those drugs are out of the picture before ovulation is triggered, because conception can occur within days of the Ovidrel injection.

Biologic agents used in RA, specifically TNF inhibitors such as adalimumab and etanercept, are generally considered compatible with the peri-conception period, though data in the first trimester are limited. Your rheumatologist should provide a written medication review before your ART cycle begins.

Thyroid Autoimmunity

Hashimoto's thyroiditis is the most common autoimmune condition in reproductive-age women, affecting approximately 10-15% of women in this age group. Thyroid autoimmunity is associated with reduced IVF success rates even when TSH is within the normal range, and with higher rates of early pregnancy loss.

HCG has direct thyroid-stimulating activity because the LH/hCG receptor and the TSH receptor share structural homology. After a 250 mcg Ovidrel injection, transient hCG-mediated thyroid stimulation can lower TSH in thyroid autoimmunity patients who are on borderline thyroid replacement. This is most pronounced if conception occurs and hCG rises further in early pregnancy.

Women with Hashimoto's should have their TSH checked within four weeks before an ART cycle, with a target TSH below 2.5 mIU/L per ASRM practice guidelines. If TSH is above that threshold, levothyroxine dose adjustment before proceeding is recommended.

Multiple Sclerosis (MS)

Women with MS typically experience a reduction in relapse rate during pregnancy, coinciding with the immunomodulatory effects of high physiological hCG and other placental factors. A single pharmacological hCG dose at ovulation trigger is far below pregnancy hCG concentrations and is unlikely to produce clinically meaningful MS effects.

The bigger consideration in MS is medication safety. Interferons (beta-1a, beta-1b) and glatiramer acetate are generally stopped before conception attempts. Natalizumab and dimethyl fumarate have more complex pregnancy data. Confirm with your neurologist that your MS medication is safely paused or switched before triggering ovulation.

Anti-hCG Antibodies: A Rare but Real Concern

Some women with systemic autoimmunity develop antibodies that cross-react with hCG. This phenomenon is documented in case series of women with SLE and in women who have received hCG-based therapies multiple times. Anti-hCG antibodies could theoretically neutralize the ovulation trigger signal, leading to failed or incomplete follicle maturation.

There is no routine clinical test for anti-hCG antibodies before an ART cycle, and the prevalence in the general autoimmune population is not well-defined by large trials. If you have undergone multiple prior ART cycles with unexplained trigger failure, mention your autoimmune diagnosis to your reproductive endocrinologist. Some centers switch to a GnRH agonist trigger (leuprolide acetate 1 mg subcutaneous, given 34-36 hours before retrieval) in patients with a history of suspected hCG resistance or antibody concerns. This is an off-label but increasingly used strategy in high-risk populations.

OHSS Risk in Women with Autoimmune Disease

Ovarian hyperstimulation syndrome occurs on a spectrum from mild bloating and pelvic discomfort to severe fluid shifts, hemoconcentration, and thromboembolic events. HCG trigger is the primary driver of OHSS because hCG has a much longer half-life than LH (approximately 24 hours versus 60 minutes), producing sustained ovarian stimulation after the trigger is administered.

OHSS rates in ART cycles range from 1% to 5% for moderate-to-severe cases in the general population. Risk is highest in women with PCOS, high antral follicle counts (AFC >14), serum estradiol above 3,500 pg/mL on the day of trigger, and women who are younger and lean.

For women with autoimmune disease, two additional factors add complexity:

1. Pre-existing vascular or coagulation abnormalities (especially in APS or SLE with prior thrombosis) mean that even mild OHSS with modest hemoconcentration carries disproportionate thrombotic risk.
2. Immunosuppressive therapy may mask early OHSS symptoms, since baseline inflammatory signs are suppressed.

Strategies your team may use to reduce OHSS risk:

• Trigger with a GnRH agonist instead of hCG (requires a GnRH antagonist protocol and is not suitable if fresh transfer is planned, since luteal support is required)
• Freeze-all embryo strategy with frozen embryo transfer in a subsequent cycle (eliminates fresh-transfer estrogen exposure)
• Intravenous albumin at time of retrieval in very high-risk cases
• Cabergoline 0.5 mg orally once daily for eight days starting on trigger day (reduces OHSS incidence by approximately 35-40% in high-risk women through VEGF pathway inhibition)

Pregnancy, Lactation, and Contraception Safety

Pregnancy

Ovidrel is given before conception, not during pregnancy. The injection itself is cleared before a pregnancy test would be positive, roughly 10-14 days after trigger in a standard ART cycle. HCG, the hormone delivered by Ovidrel, is the same molecule produced by the early placenta, so there is no known teratogenic risk from the single pre-conception trigger dose.

Women with autoimmune disease who conceive after Ovidrel trigger should plan for close obstetric and rheumatologic co-management from the first trimester. SLE and APS in particular carry elevated risks of preterm birth, preeclampsia, and fetal growth restriction, independent of which trigger agent was used.

If you are taking medications that require reliable contraception (methotrexate, leflunomide, mycophenolate mofetil), Ovidrel must not be given until those drugs are safely washed out and your care team has confirmed the washout is complete. Mycophenolate mofetil requires discontinuation at least six weeks before a planned conception attempt, per ACOG guidance, and is contraindicated in pregnancy because of high rates of fetal malformation.

Lactation

Ovidrel is indicated only for women undergoing fertility treatment, a context that does not overlap with established lactation. No pharmacokinetic data in breastfeeding women have been published. Given the biological role of hCG as a placental, not mammary, hormone, transfer into breast milk is thought to be minimal, but this is extrapolated reasoning, not studied fact. The drug is not indicated postpartum.

Contraception for Teratogenic Co-medications

If an autoimmune medication required before the ART cycle carries teratogenic risk, your team needs a documented washout and confirmation of readiness before Ovidrel trigger is appropriate. A single missed washout step can result in embryo exposure to a known teratogen at the most critical developmental window. This is not a bureaucratic formality. It is the most important medication safety check in the entire cycle.

Who This Is Right For and Who Should Pause

Women Who Can Proceed with Ovidrel

• Women with autoimmune conditions that are currently in remission or low disease activity, confirmed by validated scoring tools (SLEDAI <4 for SLE, DAS28 <2.6 for RA)
• Women on pregnancy-compatible immunosuppression (hydroxychloroquine, low-dose prednisone, azathioprine, TNF inhibitors after rheumatology sign-off)
• Women with Hashimoto's thyroiditis whose TSH has been optimized below 2.5 mIU/L before the cycle begins
• Women with MS whose neurologist has cleared them for medication pause or confirmed a pregnancy-safe regimen

Women Who Should Pause or Modify the Approach

• Women with active SLE nephritis, recent major flare, or complement consumption in the past three months
• Women with triple-positive APS who have not had hematology co-management confirmed and thromboprophylaxis in place
• Women who have not completed washout of methotrexate, leflunomide, or mycophenolate
• Women with serum estradiol above 3,500 pg/mL on trigger day and concurrent APS or prior DVT (GnRH agonist trigger and freeze-all should be strongly considered)

Dosing, Administration, and Timing for Women with Autoimmune Disease

The standard Ovidrel dose is 250 mcg (6,500 IU) subcutaneous injection, given once, approximately 34-36 hours before scheduled oocyte retrieval or timed intercourse. No dose adjustment exists for autoimmune disease specifically.

Subcutaneous injection into the abdomen or thigh is standard. Women on anticoagulation (common in APS) should note that subcutaneous injection into tissue that is regularly exposed to LMWH may develop injection-site bruising. Rotate sites and alert your nursing team to your anticoagulation status.

The injection is timed precisely. Missing the 34-36 hour window can result in premature ovulation before retrieval or in failed trigger. Set a phone alarm. Confirm the time directly with your clinic's IVF nurse coordinator, not just from a printed instruction sheet.

Monitoring After Trigger in Autoimmune Patients

Your fertility team will typically perform an ultrasound to confirm follicle collapse 24-36 hours after trigger if empty follicle syndrome is suspected. Women with autoimmune disease do not require additional post-trigger lab work beyond the standard luteal progesterone check, unless OHSS symptoms develop.

Watch for these early OHSS warning signs and contact your clinic immediately:

• Abdominal bloating that is worsening rather than improving after day 3 post-retrieval
• Significant weight gain (more than 2 lbs per day)
• Decreased urine output
• Shortness of breath

Women on anticoagulation for APS should contact their rheumatologist or hematologist concurrently if any of these signs appear, since OHSS with APS is a medical emergency requiring coordinated management.

A Note on Evidence Gaps

Women with autoimmune diseases have been systematically excluded from most ART clinical trials, including the key trials that established Ovidrel's efficacy and safety profile 1. The data used to counsel autoimmune patients about hCG trigger are drawn from general population ART trials, reproductive immunology mechanistic studies, and rheumatology-specific observational cohorts, not from dedicated randomized controlled trials enrolling women with SLE, APS, RA, or MS undergoing IVF.

This matters. Risk estimates for OHSS, trigger failure, and early pregnancy loss in this population are extrapolated, not directly measured. The ASRM Practice Committee has not published a guideline specific to hCG triggering in autoimmune disease as of 2025. Your reproductive endocrinologist is making a well-reasoned clinical judgment, not following a rigorously validated protocol designed for your specific condition.

That honesty is not a reason to avoid treatment. It is a reason to ensure your full autoimmune history, current medications, and disease activity are known to every member of your care team before your trigger shot is scheduled.